Search

脱发症是皮肤科常见疾病之一，发病率较高但临床治疗手段有限。大部分脱发症与毛囊周期的改变有关，而Omega-3及Omega-6多不饱和脂肪酸被证实通过促进或抑制毛囊细胞释放信号分子，从而促进毛囊生长、改善毛囊周期以及促进毛囊的再生。对多不饱和脂肪酸干预脱发症的研究现状及作用机制的国内外相关研究进行综述，期望能够为多不饱和脂肪酸对各类脱发症的治疗提供新思路及深入探讨脱发症的治疗方法及治疗机制提供借鉴，为利用现代分子生物技术改善脱发症提供理论依据。 Alopecia is one of the common diseases in dermatology, with a high incidence but limited clinical treatment. Most alopecia are associated with changes in hair follicle cycle, and Omega-3 and Omega-6 polyunsaturated fatty acids have been shown to promote or inhibit the release of signaling molecules by hair follicle cells to promote hair follicle growth, improve hair follicle cycle, and promote the regeneration of hair follicles. The research status of polyunsaturated fatty acids in the intervention of alopecia and the intervention mechanism were reviewed. It is expected to provide new ideas for the treatment of various types of alopecia by polyunsaturated fatty acids and to explore the treatment methods and mechanisms of alopecia,and to provide a theoretical basis for the improvement of alopecia by modern molecular biotechnology.

利用p-adic域中的同胚映射，将在超距空间上多孔介质的流体动力学模型推广至分形集，运用苏维宜定义的拟微分算子Tα，研究了一类满足初始条件的液体滴在分形多孔介质上流体动力学的反应扩散拟微分方程，得到了该方程的定解，并进一步讨论了该定解的敛散性。

调和函数在SG3 上的Dirichlet 边值问题是分形分析领域的重要研究内容之一。考虑通过垂直切割自相似图形SG3，得到SG3 上的特定定义域。对于边界值为Cantor 集的新的自相似图形，试图探讨在该定义域上的性质。在研究SG3 左半定义域上的Dirichlet 边值问题的过程中，借助SG3 上的二元有理点的调和函数值和正则导数求解格林函数。进一步，运用调和函数的有限能以及弱公式化等方法，最终得到了SG3左半定义域上的格林函数表达式及其相应的定理。

随着诊疗技术水平的提高，缺血性卒中的死亡率逐渐下降，但脑血管事件的复发率仍然 较高。因此，缺血性卒中的二级预防十分重要。社区医生对缺血性卒中患者进行科学规范的管理是 降低脑血管事件复发的关键环节，本文针对基于社区的缺血性卒中患者的二级预防特点及相关问题 做一综述。 Abstract: With the development of diagnosis and management of stroke, the mortality of ischemic stroke is gradually decreased, however, the recurrence rate of cerebral vascular disease remains very high. Therefore, the secondary prevention is particularly important. Community physician play the key role in decreasing cerebral vascular events recurrence through scientific and standard management of patients with ischemic stroke. This paper is to review the characters and relevant problems of secondary prevention medications for ischemic stroke patients in community.